The hardware and bandwidth for this mirror is donated by dogado GmbH, the Webhosting and Full Service-Cloud Provider. Check out our Wordpress Tutorial.
If you wish to report a bug, or if you are interested in having us mirror your free-software or open-source project, please feel free to contact us at mirror[@]dogado.de.
gcemod estimates covariate effects on
omega+ — the ratio of the hazard for an event of
interest to the hazard for a competing event — on either
the cause-specific (Cox) or subdistribution (Fine-Gray) scale.
Confidence intervals and p-values come from the
Lunn-McNeil stacked-model construction. Per-subject
omega = omega+/(1+omega+) is reported as a descriptive quantity so
model-predicted values can be compared with observed ones.
The workflow: (1) fit the GCE model, (2) build a risk score, (3) find cutpoints that maximize the omega+ difference between groups, (4) draw alligator plots of cumulative incidence by group, and (5) check calibration of predicted vs. observed omega+.
The package bundles two competing-risks example datasets that
illustrate contrasting GCE applications. They are provided for
illustration only and do not represent real patients. In hn
(head and neck) the event of interest (cancer recurrence) is
more frequent than the competing event (omega+ > 1). In
prostate the event of interest (distant metastasis or
prostate-cancer death) is less frequent than the competing
event (other-cause death) (omega+ < 1). Both use status:
0 = censored, 1 = event of interest, 2 = competing event, with
time in years.
data(hn)
Ind <- data.frame(event = as.integer(hn$status == 1), # recurrence
competing = as.integer(hn$status == 2)) # death w/o recurrence
Cov <- hn[, c("age", "smoker", "t_cat", "n_cat", "p16")]fit <- gcecox(hn$time, Ind, Cov, M = 5, t = 5)
summary(fit)
#> Generalized competing event model [Cox (cause-specific)]
#> Call: gcecox(Time = hn$time, Ind = Ind, Cov = Cov, M = 5, t = 5)
#> n = 1000; events of interest = 391; competing events = 243; t = 5
#>
#> --- omega+ ratio (event of interest vs. competing event) ---
#> exp(coef) (omega+ ratio) lower .95 upper .95 P-value
#> age 0.93295 0.91310 0.95323 0.00000
#> smoker 0.71795 0.49232 1.04697 0.08516
#> t_cat2 1.00580 0.40885 2.47437 0.98995
#> t_cat3 0.80732 0.33493 1.94596 0.63349
#> t_cat4 0.90705 0.37726 2.18085 0.82747
#> n_cat1 1.26583 0.71349 2.24574 0.42031
#> n_cat2 1.30179 0.84012 2.01715 0.23788
#> n_cat3 0.91398 0.47167 1.77110 0.78987
#> p16 0.64152 0.38994 1.05542 0.08053
#>
#> Lunn-McNeil omnibus test: chi-sq = 49.215, df = 9, p = <1e-04Each P-value tests whether that covariate shifts omega+
(event of interest vs. competing event); the omnibus test asks the same
jointly.
The Fine-Gray version uses the same interface:
The linear predictor is stored in fit$riskscore, and
per-subject omega+ / omega at time t in
fit$omegaplus / fit$omega.
head(data.frame(riskscore = fit$riskscore,
omegaplus = fit$omegaplus, omega = fit$omega))
#> riskscore omegaplus omega
#> 1 0.3111360 2.4611482 0.7110785
#> 2 1.6653168 9.5334700 0.9050645
#> 3 0.5548256 3.1402976 0.7584715
#> 4 -0.5955188 0.9939913 0.4984933
#> 5 -0.1996211 1.4767900 0.5962516
#> 6 0.4918702 2.9486935 0.7467517Risk groups are distinguished by color and event types by line type (event of interest solid, competing event dashed) on a single panel.
Running the same workflow on prostate shows the opposite
regime. Here the competing event (other-cause death) dominates, so
omega+ ratios and the risk score point the other way, and the alligator
jaws open with the competing-event CIF on top.
Lunn M, McNeil D (1995) Applying Cox regression to competing risks. Biometrics 51:524–32.
Carmona R, et al. (2014) Validated competing event model for the stage I-II endometrial cancer population. Int J Radiat Oncol Biol Phys 89:888–98.
Carmona R, et al. (2016) Improved method to stratify elderly patients with cancer at risk for competing events. J Clin Oncol 34:1270–77.
Mell LK, et al. (2019) Nomogram to predict the benefit of intensive treatment for locoregionally advanced head and neck cancer. Clin Cancer Res 25:7078–7088.
Zakeri K, et al. (2020) Predictive classifier for intensive treatment of head and neck cancer. Cancer 126:5263–5273.
Mell LK, et al. (2024) Effects of androgen deprivation therapy on prostate cancer outcomes according to competing event risk. Eur Urol 85:373–381.
These binaries (installable software) and packages are in development.
They may not be fully stable and should be used with caution. We make no claims about them.
Health stats visible at Monitor.